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Purpose: Approximately 20 to 40% of patients with surgically
resected stage I non-small cell lung cancer (NSCLC) will develop
recurrent disease. Positron emission tomography (PET) with 2-[18F]
fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC.
We conducted this study to determine whether the preoperative
maximum tumor standardized uptake value (SUVmax) was associ-
ated with recurrence in patients with resected stage I NSCLC.
Patients and Methods: We identified consecutive patients who
underwent curative surgical resection for stage I NSCLC between
1999 and 2003 who had preoperative FDG-PET imaging. Patients
were divided into two cohorts based on SUVmax above or below the
median for the group. Recurrence rates were estimated by the
Kaplan-Meier method and overall survival was analyzed as a sec-
ondary end point.
Results: Of 136 patients who met inclusion criteria, 77 (57%) had
T1 and 59 (43%) had T2 tumors. The median follow-up time was 46
months and 32 patients had a disease recurrence. The median
SUVmax was 5.5. The 5-year estimates of recurrence rates for
patients with low and high SUVmax were 14% and 37%, respectively
(p  0.002), with 5-year overall survivals of 74% and 53%,
respectively (p 0.006). In multivariate analyses based on SUVmax,
T-classification, age, and histology, high SUVmax was indepen-
dently associated with recurrence (p  0.002) and mortality (p 
0.041).
Conclusion: High SUVmax (5.5) on preoperative FDG-PET is an
independent predictor of relapse and death in resected stage I
NSCLC. Prospective trials of adjuvant chemotherapy in patients
with stage I NSCLC and high SUVmax should be considered.
Key Words: Non-small cell lung cancer, Prognosis, PET, Imaging,
Stage I, Early stage, Surgery outcomes.
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Lung cancer is the leading cause of cancer-related death inboth men and women, with an estimated 213,380 new
cases and 160,390 patients dying from this disease in 2007 in
the United States.1 Nearly 87% of lung cancer patients are
diagnosed with non-small cell lung cancer (NSCLC), and of
these, approximately 30% of patients are candidates for
curative resection.2,3 It has now become an accepted practice
to offer adjuvant chemotherapy for patients with resected
stage IB–III NSCLC based on the results of several prospec-
tive studies that have demonstrated a statistically significant
and clinically meaningful survival advantage with this ap-
proach.4–6 Nevertheless, subset analyses of stage IB patients,
and a large trial of only stage IB patients, have failed to show
a significant survival advantage in this population.7 Identify-
ing stage I patients who are at highest risk of relapse could
help determine which patients are most likely to benefit from
adjuvant chemotherapy.
Positron emission tomography (PET) with the glucose
analogue 2-[18F]fluoro-2-deoxy-D-glucose (FDG) has an es-
tablished role in the treatment of NSCLC. It enhances the
accuracy of clinical staging, improving patient selection for
surgical treatment.8–10 Tumor FDG uptake, as measured by
the standardized uptake value (SUV), has been demonstrated
to correlate with several predictors of outcome in NSCLC.
Accordingly, several studies have addressed the relationship
between the tumor SUV and outcome in NSCLC; we have
recently reviewed the available literature on this topic.11
These studies have in aggregate suggested that the SUV for
FDG may be a powerful surrogate marker for outcome in
NSCLC. Nevertheless, the patient populations in these stud-
ies have typically been heterogeneous, often including sub-
jects with NSCLCs of several different stages and histologies.
We thus undertook a review of the Washington University
experience to determine whether we could confirm the pre-
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dictive value of the SUV for FDG in a patients with stage I
NSCLC treated uniformly with surgery and no adjuvant
chemotherapy or radiation. We excluded patients with bron-
chioalveolar carcinoma given the low FDG uptake of many of
these tumors and the apparently different biologic behavior.12
PATIENTS AND METHODS
We reviewed the medical records of all patients with
stage I NSCLC of nonbronchioalveolar carcinoma pathology,
as staged according to the 1997 revised International Sys-
tem,13 who underwent curative resection from January 1,
1999, to December 31, 2003, and for whom complete patho-
logic staging data were available. Patients who underwent
FDG-PET within 120 days before definitive resection were
included in this analysis. Our institutional review board
approved this study.
We collected data regarding age at diagnosis, timing of
FDG-PET, timing of surgery, tumor, node, metastasis stag-
ing, the maximum SUV (SUVmax) of the primary tumor,14
extent of surgery, time to recurrence, time to last follow-up,
time to death, and cause of death. All original pathology
reports were reviewed and data were collected from the
review of all available radiologic and pathologic reports; clinic
charts from thoracic surgery, radiation oncology, and medical
oncology; and inpatient electronic charts. Date of death was
confirmed through the Social Security Death Index.
PET imaging over the course of this study was con-
ducted on three different scanners, including a Siemens
ECAT EXACT scanner (Siemens, Knoxville, Tennessee), a
Phillips/ADAC CPET-Plus scanner (Phillips, Milpitas, Cali-
fornia), and a Siemens Biograph LSO Duo hybrid PET/
computed tomography scanner (Siemens, Knoxville, Tennes-
see). PET imaging was performed in routine clinical fashion
in accordance with a standard protocol. All of the PET studies
were first interpreted clinically and then were subsequently
evaluated a second time for this study by a radiologist,
fellowship trained in nuclear medicine. The SUVmax of the
primary bronchogenic carcinoma was measured by placing a
region of interest (ROI) around the visible tumor, with careful
attention to avoid inclusion of any myocardium. Standard
software tools supplied by the manufacturer of each scanner
were used. When the primary tumor was seen on PET, the
ROI was placed around the visible tumor, with careful attention
to avoid inclusion of any myocardium. For tumors that were not
seen on PET, no measurement was made on conventional PET
studies performed with either the ECAT EXACT or the CPET,
and the patient was assigned to the low-SUV group (see later).
For studies performed with the biograph where the lesion was
not visible on PET, the ROI was placed around the lesion seen
on computed tomography lung windows.
Statistical Analysis
To assess the prognostic value of the SUVmax, we
subdivided the patients into two cohorts: those with values for
SUVmax below the median versus those with SUVmax greater
than or equal to the median for the population. This decision
was made a priori to avoid introduction of bias into the study.
Overall survival (OS) was defined as the interval from sur-
gery to death from any cause and those patients who re-
mained alive were censored at the date of last clinical contact.
Time to recurrence was defined as time from the date of
surgery to the recurrence of lung cancer. Patients without
recurrence were censored from the analysis at the time of last
negative follow-up encounter, death without evidence of
recurrence, or diagnosis of a second primary lung cancer. OS
and recurrence rates were estimated by Kaplan-Meier product
limit method. The log-rank test was used to detect the
potential association between each covariate and survival or
recurrence. A multivariate Cox proportional hazards model
was fitted to identify independent risk factors and to adjust for
the potential effects of known risk factors (age, T-classifica-
tion, and histology). Interaction terms with SUVmax were
entered into the model one at a time.
To avoid the assumption of linear relationships as well
as for a better interpretation of the results, the continuous
variables, age, and SUVmax were dichotomized. Tumor size
was not analyzed as a covariate because of its interdepen-
dence with T-classification. A multivariate Cox proportional
hazards model was fitted to identify independent risk factors.
To better understand the relationship between SUVmax and
outcomes, the assumption of linearity was also assessed. In
this analysis, a smoothed line is imposed on the scatter plot of
SUVmax against the martingale residuals, which were ob-
tained from the multivariate Cox model containing all vari-
ables but SUVmax. If the linearity assumption is well satisfied,
the plot shows an approximately straight line. This plot also
provides useful information for choosing the appropriate
cut-off point when the linearity assumption is violated. The
statistical analysis was performed with the statistical package
SAS version 9. A p value under 0.05 was taken to indicate
statistical significance and all tests were two-sided.
RESULTS
We identified 136 consecutive patients diagnosed with
stage I NSCLC between 1999 and 2003 who met our selec-
tion criteria. Patient characteristics are shown in Table 1.
None of the patients received adjuvant chemotherapy or
radiotherapy. Of 136 patients with stage I NSCLC, 77 (57%)
TABLE 1. Characteristics of Resected Stage I NSCLC
Subjects, Grouped by SUVmax 5.5 or 5.5
Variables
Low SUVmax High SUVmax
pn % n %
Total subjects 65 51 71 49
Age at diagnosis, median 65 69 0.004
T-classification 0.001
1 46 71 31 44
2 19 29 40 56
Size (cm), median 1.9 3.4 0.001
Histology 0.001
Adenocarcinoma 46 68 25 36
Squamous 13 23 34 45
Other 6 10 12 16
SUVmax, maximum tumor standardized uptake value.
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had T1 and 59 (43%) had T2 tumors. Ten patients with T2
tumors had a tumor size of 3 cm or less but presence of
pleural invasion. The median follow-up time was 46 months,
and 32 patients (24%) had a recurrence of their disease.
Sixteen patients died within 1 year of surgery, only two of
these had a disease recurrence. Most patients had adenocar-
cinoma (71 patients) or squamous cell carcinoma (47), but
other histologies were also present with six patients having
adenosquamous carcinoma and 10 patients having large-cell
carcinoma, with or without neuroendocrine features. In two
patients, no histologic subtype could be determined. PET was
performed at a median of 15 days before surgery (range
0–113 days).
The median SUVmax for the population was 5.5. Patients
with a higher tumor SUVmax were more likely to be older and
have larger or T2 tumors, and were less likely to have adeno-
carcinoma (Table 1). Only 10 patients with a low SUVmax had
a recurrence of their disease (14%), whereas 22 patients (33%)
in the high-SUVmax group had a recurrence. The estimated
5-year recurrence rate in the low-SUVmax group was 14%,
compared with 37% in the high-SUVmax group (p 0.002). The
5-year OSwas correspondingly higher in the low-SUVmax group
(74% versus 53%, p  0.006; Table 2 and Figures 1 and 2). Of
note, patients of other histologies (not squamous or adenocarci-
noma) had particularly poor outcomes with 5-year recurrence
rates and mortality rates of 55% and 66%, respectively.
In the univariate analysis for other covariates, histology
and T-classification were significantly associated with recur-
rence (Table 2). T-classification and age (70 versus 70)
FIGURE 1. Recurrence rates based on SUVmax where verti-
cal bars within each curve represent the distributions of cen-
sored cases. SUV, standardized uptake value; SUVmax, maxi-
mum tumor standardized uptake value.
TABLE 2. Univariate Analysis for Predictors of Outcome in






5-yr p 5-yr p
SUVmax 0.002 0.006
5.5 65 14 74
5.5 71 37 53
T-classification 0.035 0.002
T1 77 17 73
T2 59 36 52
Histology 0.016 0.19
Adenocarcinoma 71 27 69
Squamous 47 12 65
Others 18 55 34
Age 0.53 0.006
70 79 22 74
70 57 28 52
SUVmax, maximum tumor standardized uptake value.
FIGURE 2. Overall survival based on SUVmax where vertical
bars within each curve represent the distributions of cen-
sored cases. SUV, standardized uptake value; SUVmax, maxi-
mum tumor standardized uptake value.
Goodgame et al. Journal of Thoracic Oncology • Volume 3, Number 2, February 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer132
were significantly associated with OS. In the multivariate
analysis, high SUVmax was independently associated with
recurrence, having a hazard ratio (HR) of 3.5, with 95%
confidence intervals (CI) of 1.6 to 7.7. Nonsquamous histol-
ogy was also independently associated with recurrence
(HR  2.8, 95% CI  1.2–6.7; Table 3). High SUVmax was
also independently associated with worse survival in the
multivariate analysis (HR  1.9, 95% CI  1.03–3.57). Age
and T2 tumor status were also independently associated with
worse OS with HRs of 2.12 and 2.06, respectively. No interac-
tion terms between covariates were statistically significant.
An analysis of the residuals for recurrence and OS as
described in the methods showed that the relationships be-
tween SUVmax and recurrence, and SUVmax and survival,
were dependent but nonlinear. This analysis confirmed that
median SUVmax was an appropriate cut-off point to distin-
guish between high- and low-risk patients based on our data
(data not shown).
DISCUSSION
New risk stratification markers and models are urgently
needed to evaluate which patients with resected stage I
NSCLC are at highest risk for relapse and stand to benefit
most from adjuvant chemotherapy. In this series of 136 stage
I NSCLC patients, higher preoperative SUVmax was strongly
associated with poor outcomes.
Several other investigators have also retrospectively
evaluated their experience, attempting to correlate SUV with
outcomes in patients with NSCLC, and we have recently
reviewed these publications.11 Multiple studies have shown a
correlation between SUV and stage, survival or disease-free
survival. The majority of these publications have grouped all
stages of NSCLC. Cerfolio et al. published a large series of
315 patients with resected NSCLC, which included 141 stage
I patients. Higher SUV correlated with stage, as well as with
recurrence and survival. Multivariate analysis of the entire
cohort found that SUV 10 was the best independent pre-
dictor of disease-free survival and survival. A multivariate
analysis of the stage I patients was not presented.15 In a more
recent study by Ohtsuka et al., SUVmax was correlated with
outcomes for 98 stage I patients, limited to those with
adenocarcinoma. A value of 3.3 was found to be the optimum
cut-off point. Twelve recurrences were identified and 10 of
these were in the high-SUVmax group, which approached
statistical significance by multivariate analysis (p  0.079).16
In the current study, the number of patients (136) and
recurrences (32) allowed for a multivariate analysis of
factors predictive of recurrence and survival in a pure stage
I population. Patients with SUVmax 5.5 (the median for
the group) had a statistically significant increase in recur-
rence rate and mortality, which was independent of other
standard risk factors (age, histology, and T-classification)
by multivariate analysis. As shown in Figure 1, the time to
recurrence in patients with a high SUVmax was shorter than
that in patients with a lower SUVmax (median time of 11
months versus 25 months).
The precise definitions and implications of high- and
low-risk PET findings have yet to be determined. Ohtsuka
et al. found that an SUVmax of greater than 3.3 best defines
a high-risk population,16 whereas our data suggest that an
SUVmax of approximately 5 is more appropriate. Never-
theless, their study was limited to adenocarcinoma, which
has been shown to have a lower SUV in other studies17,18
as well as in our own data (median SUVmax of 4.2 versus
8.4 for squamous).
What is the next logical step in refining this prog-
nostic tool? It should be fairly straightforward to develop
a prospective registry of patients with resected T1 and T2
NSCLC with preoperative PET imaging performed accord-
ing to standardized protocols. This would allow for more
accurate estimates of relapse risk and identification of the
most appropriate SUV groupings.
Nevertheless, more important than the prognostic
question, is the question of whether these patients would
benefit from adjuvant chemotherapy. Current evidence
from clinical trials does not support the use of adjuvant
chemotherapy in unselected stage I NSCLC patients, but
based on our retrospective data, stage I patients with high
SUVmax may be more than three times more likely to have
recurrences of their disease. Higher recurrence rates suggest
that a survival benefit from chemotherapy might be easier to
establish in this population than in an unselected group.
Therefore, prospective clinical trials of adjuvant chemother-
apy in patients with stage I NSCLC and SUVmax greater than
5 should be strongly considered.
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